As on Thursday, Candel Therapeutics Inc (NASDAQ: CADL) got off with the flyer as it spiked 3.71% to $5.03, before settling in for the price of $4.85 at the close. Taking a more long-term approach, CADL posted a 52-week range of $3.79-$14.60.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -43.86%. Meanwhile, its Annual Earning per share during the time was -43.86%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 40.03%. This publicly-traded company’s shares outstanding now amounts to $49.25 million, simultaneously with a float of $36.44 million. The organization now has a market capitalization sitting at $268.22 million. At the time of writing, stock’s 50-day Moving Average stood at $5.18, while the 200-day Moving Average is $6.45.
Candel Therapeutics Inc (CADL) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Candel Therapeutics Inc’s current insider ownership accounts for 27.27%, in contrast to 38.11% institutional ownership. According to the most recent insider trade that took place on Mar 18 ’25, this organization’s Chief Medical Officer sold 45,316 shares at the rate of 8.76, making the entire transaction reach 396,995 in total value, affecting insider ownership by 52,493. Preceding that transaction, on Mar 18 ’25, Company’s Chief Scientific Officer sold 32,146 for 8.76, making the whole transaction’s value amount to 281,673. This particular insider is now the holder of 96,527 in total.
Candel Therapeutics Inc (CADL) Earnings and Revenue Records
Candel Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 40.03% and is forecasted to reach -1.29 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 28.77% through the next 5 years, which can be compared against the -43.86% growth it accomplished over the previous five years trading on the market.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Let’s observe the current performance indicators for Candel Therapeutics Inc (CADL). It’s Quick Ratio in the last reported quarter now stands at 4.64.
In the same vein, CADL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.34, a figure that is expected to reach -0.27 in the next quarter, and analysts are predicting that it will be -1.29 at the market close of one year from today.
Technical Analysis of Candel Therapeutics Inc (CADL)
Through scrutinizing the latest numbers posted by the [Candel Therapeutics Inc, CADL], it can be observed that its last 5-days Average volume of 0.94 million was lower the volume of 1.09 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 39.09% While, its Average True Range was 0.34.
Raw Stochastic average of Candel Therapeutics Inc (CADL) in the period of the previous 100 days is set at 8.27%, which indicates a major fall in contrast to 32.05% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 60.79% that was lower than 95.89% volatility it exhibited in the past 100-days period.
